Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 18Neoplasms 18Breast Neoplasms 16Colorectal Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Lung Neoplasms 10Urinary Bladder Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Hematopoietic and Lymphatic System Neoplasm 6Hematologic Neoplasms 6Ovarian Neoplasms 5Neoplasm Metastasis 5Triple Negative Breast Neoplasms 4Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Multiple Myeloma 3Mouth Neoplasms 3Hematopoietic and Lymphoid System Neoplasm 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Sarcoma 2Radiodermatitis 2Peritoneal Neoplasms 2Pathologic Complete Response 2Parotid Neoplasms 2Motor Activity 2Melanoma 2Malignant Solid Neoplasm 2

Interventions

darolutamide 3Pluvicto 3Docetaxel 3testosterone 17 beta-cypionate 2sipuleucel-T 1lactitol 1fludarabine phosphate 1fludarabine 1enzalutamide 1ebastine 1cabozantinib 1cabazitaxel 1Standard of Care 1Prednisone 1Prednisolone 1PSMA-617 1Gonadotropin-Releasing Hormone 1Cyclophosphamide 1Bortezomib 1Blood Specimen Collection 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Metastatic Castration-resistant Prostate Cancer × Standard of Care × Clear all
NCT06401980 2026-03-30

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Swiss Cancer Institute

Phase 2 Recruiting
162 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡